BridgeBio Pharma
BBIO
BBIO
247 hedge funds and large institutions have $6.76B invested in BridgeBio Pharma in 2023 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 89 increasing their positions, 77 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
16% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 77
12% more funds holding
Funds holding: 221 → 247 (+26)
2.95% less ownership
Funds ownership: 99.16% → 96.21% (-2.9%)
Holders
247
Holding in Top 10
15
Calls
$110M
Puts
$90.1M
Top Buyers
| 1 | +$93M | |
| 2 | +$75.6M | |
| 3 | +$74.3M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.5M |
| 5 |
BlackRock
New York
|
+$36.6M |
Top Sellers
| 1 | -$56.2M | |
| 2 | -$53.2M | |
| 3 | -$33.7M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$25.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$16.8M |